Pharming (PHAR) Receivables (2019 - 2025)

Pharming's Receivables history spans 7 years, with the latest figure at $56.6 million for Q4 2025.

  • Quarterly results put Receivables at $56.6 million for Q4 2025, changed 0.38% from a year ago — trailing twelve months through Dec 2025 was $56.6 million (changed 0.38% YoY), and the annual figure for FY2025 was $56.6 million, changed 0.38%.
  • Receivables for Q4 2025 was $56.6 million at Pharming, roughly flat from $56.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $56.6 million in Q4 2025 to a low of $28.7 million in Q4 2022.
  • The 5-year median for Receivables is $48.3 million (2023), against an average of $44.5 million.
  • The sharpest move saw Receivables fell 12.8% in 2021, then surged 68.09% in 2023.
  • Year by year, Receivables stood at $32.3 million in 2021, then fell by 11.16% to $28.7 million in 2022, then surged by 68.09% to $48.3 million in 2023, then increased by 16.8% to $56.4 million in 2024, then rose by 0.38% to $56.6 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $56.6 million, $56.4 million, and $48.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.